Keeping Track: US FDA Approves Spinraza And Rubraca, Delays Ocrevus; Plus Submissions Galore
Executive Summary
The latest drug development news and highlights from our FDA Performance Tracker.
You may also be interested in...
US FDA Limits GMP Exemption For ‘N of 1’ Investigational New Drugs
Agency drafts guidance on how to apply requirements for chemistry, manufacturing and controls, and for good manufacturing practices, to bespoke antisense nucleotides.
AAA Ramps Up Lutathera Launch And Plans Expansion Under Novartis Ownership
Advanced Accelerator Applications is ramping up the launch of the first-in-class peptide receptor radionuclide therapy (PRRT), but Novartis has much broader ambitions for the radiopharmaceutical platform. AAA President Susanne Schaffert talked to Scrip about the growth strategy.
Keeping Track: Shutdown Edition
The latest drug development news and highlights from our US FDA Performance Tracker.